Filed in archive
Studies
, Treatment
by Gloria Gamat on October 17, 2006
This discovery is potentially useful for providing longer-lasting treatment for osteoarthritis, the most common form of arthritis.
The researchers modified a drug called interleukin-1 receptor antagonist (IL1RA) -a protein-- improved by attaching a second protein that clumps together at normal body temperatures.
According to the researchers, the combined drug likewise would assemble into clumps in the body to serve as "drug depots" that gradually release active drug particles.
Lori Setton, associate professor of biomedical engineering and surgery stated:
"Although the conventional drug is being used for autoimmune diseases, no one yet knows how much of it would be needed to achieve a therapeutic effect for osteoarthritis.
Current estimates suggest it would require perhaps two injections per week of the unmodified drug. With this advance, we believe treatments could go from twice a week to perhaps twice a month, and that would be a huge clinical gain."
The Duke Research team reported an initial proof-of-concept study on Saturday (Oct. 14) at the Biomedical Engineering Society annual meeting in Chicago and related findings online in the Journal of Controlled Release.
Find more details from Duke University News.
Permalink: Engineered Anti-Inflammatory Drug (Interleukin-1 Receptor Antagonist) Prolongs Arthritis Relief
Tags:
interleukin1
receptor
antagonist
IL1RA
arthritis
osteoarthritis
antiinflammatory
drug
anti
interleuk
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/39489
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Engineered Anti-Inflammatory Drug (Interleukin-1 Receptor Antagonist) Prolongs Arthritis Relief:
|
Rating: 7.67 out of 3 vote(s) cast.
|
Response from:
cheap medications
(10/10/07 6:28am)
I just love it when progresses are made in this field. I think old people should live their last days decent.
Response from:
Trusted.MD Network
The FDA has just approved a new orphan drug for the treatment of rare inflammatory syndromes.
Response from:
Trusted.MD Network
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
